{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Histogen, Inc. overvalued or undervalued?
As of October 15, 2023, Histogen, Inc. is considered overvalued due to its high price-to-earnings ratio of 45.2 and price-to-book ratio of 3.8, significantly exceeding industry averages and indicating that investors are paying a premium compared to peers like Aclaris Therapeutics and Revance Therapeutics.
Is Histogen, Inc. technically bullish or bearish?
As of October 1, 2023, there is insufficient technical data for Histogen, Inc. to determine a bullish or bearish outlook.
Who are in the management team of Histogen, Inc.?
As of March 2022, the management team of Histogen, Inc. includes Dr. David Crean (Chairman), Mr. Richard Pascoe (CEO), and directors Dr. Stephen Chang, Mr. Jonathan Jackson, Dr. Steven Mento, Mr. Brian Satz, and Mr. Hayden Yizhuo Zhang. They oversee the company's strategic direction and operations.
How big is Histogen, Inc.?
As of Jun 18, Histogen, Inc. has a market capitalization of 0.00, with net sales of 0.03 million and a net profit of -12.38 million over the latest four quarters. As of Dec 22, the company reported shareholder's funds of 14.40 million and total assets of 19.07 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
